Abstract: Epidural steroid injections (ESIs) are the most widely utilized pain management procedure in the world, their use supported by more than 45 placebo-controlled studies and dozens of systematic reviews. Despite the extensive literature on the subject, there continues to be considerable controversy surrounding their safety and efficacy. The results of clinical trials and review articles are heavily influenced by specialty, with those done by interventional pain physicians more likely to yield positive findings. Overall, more than half of controlled studies have demonstrated positive findings, suggesting a modest effect size lasting less than 3 months in well-selected individuals. Transforaminal injections are more likely to yield positive results than interlaminar or caudal injections, and subgroup analyses indicate a slightly greater likelihood for a positive response for lumbar herniated disk, compared with spinal stenosis or axial spinal pain. Other factors that may increase the likelihood of a positive outcome in clinical trials include the use of a nonepidural (eg, intramuscular) control group, higher volumes in the treatment group, and the use of depo-steroid. Serious complications are rare following ESIs, provided proper precautions are taken. Although there are no clinical trials comparing different numbers of injections, guidelines suggest that the number of injections should be tailored to individual response, rather than a set series. Most subgroup analyses of controlled studies show no difference in surgical rates between ESI and control patients; however, randomized studies conducted by spine surgeons, in surgically amenable patients with standardized operative criteria, indicate that in some patients the strategic use of ESI may prevent surgery.
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(Reg Anesth Pain Med 2013;38: 175Y200) E pidural steroid injections are one of the most commonly performed procedures in medicine. It is a topic that seems to transcend pain medicine, with a domain that extends across multiple specialties and to some extent even outside medicine. Yet, there are few subjects that have generated such intense controversy. Legions of articles have been written on the subject, and, arguably, there may be more research on this treatment than for any other interventional therapy in medicine. In fact, so much has been written on the subject that a mythological aura now exists that this is an essential treatment, which makes it even more challenging for patients, and even nonpain physicians, to be able to critically evaluate their effectiveness. The purpose of this article was to provide an evidence-based review on the subject, to include mechanisms of action, efficacy, risks, and cost-effectiveness.
SEARCH STRATEGY AND LEVELS OF EVIDENCE
Articles included in this review were selected by searches of the PubMed, MEDLINE, EMBASE, and OVID databases from 1953 to February 2013 using various combinations of the search terms ''epidural steroid,'' ''caudal,'' ''transforaminal,'' ''selective nerve block,'' ''selective nerve root block,'' ''segmental nerve block,'' ''corticosteroid,'' ''radiculopathy,'' ''radicular pain,'' ''sciatica,'' ''pain,'' ''low back,'' ''lumbar,'' ''thoracic,'' ''midback,'' ''cervical,'' ''neck,'' ''spinal,'' and ''spine.'' Controlled trials, comparative-effectiveness studies, review articles, and case reports were all considered for inclusion, without language restrictions. The reference lists of all articles were searched for pertinent references that were missed during the initial screening.
Evidence was synthesized, and recommendations were based on a conglomeration of factors including weighted evidence in accordance with the Oxford Centre for Evidence Based Medicine, 1 consensus guidelines when relevant, and perceived bias. Levels of evidence cited in referenced systematic reviews were either based on US Preventive Services Task Force (USPSTF) criteria 2 or, if classified by another scale, conveyed descriptively (eg, fair, good [ Table 1 ]). For comparativeeffectiveness studies (ie, type of epidural steroid injection [ESI] and type of corticosteroid), evidence of superiority was described using USPSTF levels of certainty (Table 2) .
HISTORY
The first therapeutic epidural injection was performed in 1885 by neurologist James Leonard Corning, 3 an American-born expatriate. Dr Corning 4 made history by injecting the local anesthetic cocaine between the lower lumbar spinous processes, first in a dog, then in a healthy man to treat ''seminal incontinence'' and ''addiction to masturbation.'' Controversy surrounds whether Corning actually injected the solution into the intrathecal space, 5 but because no cerebrospinal fluid was reported, this is widely considered to be the first therapeutic epidural injection. 6 In 1901, the French physicians Jean-Anthanase Sicard and Ferdinand Cathelin separately described the first use of epidurals to treat radicular pain when they injected dilute solutions of cocaine through the sacral hiatus in patients with intractable sciatica. 7, 8 In 1930, Evans 9 reported a 14% success rate with the caudal injection of 40 to 80 mL of solution, with no difference in outcomes noted between local anesthetic and saline. Although the practice of using epidurals to provide surgical anesthesia eventually supplanted its use as a treatment for back pain, the use of caudal 10 and lumbar epidural 11 injections for the treatment of chronic back pain continued to evolve.
The epidural injectate used to treat chronic pain remained a mixture of local anesthetic and saline up to the 1950s 12, 13 when the use of corticosteroids to manage lumbar radicular pain was first recorded in 1953 by Lievre et al. 14 In 1961, Goebert et al 15 published a case series of 113 patients suffering from lumbar radiculopathy who were successfully treated with the epidural administration of procaine and hydrocortisone acetate. The first modern controlled trial evaluating ESIs was performed in 1970 by Swerdlow and Sayle-Creer. 16 
EPIDEMIOLOGY
It is difficult to overestimate the socioeconomic burden posed by spinal pain. The annual cost to treat back pain alone exceeds $100 billion by some estimates, with more than half due to lost productivity. 17, 18 For low back pain (LBP), the most commonly cited lifetime prevalence rates range between 40% and 70%, with an annual prevalence rate ranging between 10% and 30% according to some estimates. 18, 19 Among those who develop LBP, approximately 30% will develop either chronic pain or frequent reccurrences. 20 In individuals younger than 45 years, back pain is the leading cause of disability. 21 Neck pain is less well publicized, but also exacts a steep socioeconomic toll. Nearly two-thirds of patients will experience a significant episode of neck pain over the course of their lives, with the annual prevalence around 30%. 22Y24 The economic costs of neck pain have not been as well studied as for back pain, but are nevertheless significant and growing. 25, 26 There are various schemes for categorizing chronic pain, with perhaps the most relevant being classification into neuropathic and nociceptive pain, as this affects treatment decisions at nearly every level. For patients with chronic LBP, studies utilizing validated instruments have demonstrated that between 17% and 55% have pain that is primarily neuropathic in nature, with a median of 41%. 27Y31 Among neck pain sufferers, no studies have evaluated the proportion of individuals with neuropathic pain, although epidemiological studies suggest an annual incidence of between 1 and 3.5 per 1000 people.
32Y34
Epidural steroid injections are by far the most frequently performed procedures in pain clinics throughout the United States, more than doubling between 2000 and 2008. 35 Although they have historically been utilized for spinal pain of all types, they are widely acknowledged to work better for neuropathic pain. There have arguably been more reviews and more randomized controlled studies (945) evaluating ESI for spinal pain than for any other treatment for a single condition. Yet, there continues to be enormous controversy surrounding the shortand long-term efficacy, effectiveness, and, more recently, safety of this treatment.
MECHANISMS OF ACTION
The mechanisms by which steroids exert their analgesic effects have been debated for many years. Corticosteroids inhibit the enzyme phospholipase A 2 , which catalytically hydrolyzes the bond converting membrane phospholipids into arachidonicacid and lysophospholipids. Phospholipase A 2 is itself an inflammatory mediator present in elevated concentrations in herniated and degenerative intervertebral disks, 36 but its main role is as the rate-limiting factor involved in the production of arachidonic acid, which is the principal substrate for the cyclo-oxygenase and lipo-oxygenase pathways. Metabolism by these pathways results in the formation of the 4 different classes of eicosanoids: prostaglandins, prostacyclins, thromboxanes, and leukotrienes. Prostaglandins, along with these other arachidonic acid byproducts, can cause or exacerbate pain via their inflammatory effects and ability to sensitize peripheral nociceptors. 37 In addition to their antiinflammatory effects, steroids may inhibit pain via their ability to suppress ectopic discharges from injured nerve fibers 38 and depress conduction in normal unmyelinated C fibers. Several proposed mechanisms for the beneficial effects do not involve steroids. The injection of local anesthetic can increase blood flow to ischemic nerve roots 40 and, similar to steroids, suppress ectopic discharges from injured neurons and slow or halt nociceptive transmission. 41 Moreover, the administration of saline, local anesthetic, or any nonsteroid solution can exert an analgesic effect via the washout of inflammatory cytokines and the adhesiolysis of scar tissue. 42, 43 The effect of nonsteroid solutions was illustrated in a systematic review by Rabinovitch et al, 44 who found a significant correlation between epidural volume and pain relief irrespective of steroid dose in the immediate (G6 weeks; r = 0.80, P = 0.002) and intermediateterm (3 months to 1 year; r = 0.95; P = 0.014) and a trend toward significance in the short term (6 weeks to 3 months; r = 0.50; P = 0.17). When different volumes were used in the treatment and control groups, the effect size for ESI was 0.81, which favorably compared with the effect size when the same volumes were injected (0.07; P = 0.001).
39

EFFICACY AND TYPE OF INJECTION
The efficacy of ESI in patients is difficult to determine because of the multiple and heterogeneous factors associated with ESI and their outcome assessment. Differences in injection route, region, control group, injectate characteristics, and patient pathology contribute to variation in outcomes and present challenges in the interpretation of existing studies regarding ESI. Yet, there is a widespread consensus across all specialties that ESI provides at least short-term benefit in well-selected patients. What is less clear is which patients are likely to benefit from the intervention, and whether they provide long-term relief. The conceptual appeal of ESI is that the relief from the procedure will allow the body the time to heal itself, without the long-term sequelae associated with central sensitization. 45 Greater than 70% of patients with radiculopathy will recover within 6 months, 46, 47 and a similar proportion will experience resorption of a herniated disk within 1 year of presentation. 48, 49 Another rationale for the use of ESI is that the evidence in support of the procedure is more robust (ie, more clinical trials showing benefit), and the risk-benefit ratio more favorable, compared with other treatments. Among randomized clinical trials evaluating surgery for neuropathic LBP and neck pain irrespective of etiology, most demonstrate temporary (ie, 6 months) but not long-term benefit. 50Y52 For medications, the evidence is either negative or conflicting at best. (Fig. 1) . As shown in Table 3 , a majority of studies comparing different routes of injection support the general consensus among practitioners that transforaminal ESI is superior to IL or caudal ESI. 55Y67 Transforaminal ESI was superior to IL ESI or caudal in 5 of 8 randomized controlled trials (RCTs) comparing the 2 routes, and 3 of 5 retrospective studies. Studies failing to show benefit included that of Kolsi et al, 58 which nonsignificantly favored TF over IL ESI for initial pain reduction, and that of Candido et al, 56 which was underpowered and used a variation on the classic IL approach.
Because the injectate is administered closer to the area of pathology, one might suspect that IL ESIs are more efficacious than caudal ESI. However, a review of randomized clinical trials found that a higher proportion of controlled studies evaluating caudal ESIs were positive than those evaluating IL ESIs (Fig. 2) . The likely explanation for this paradoxical phenomenon is that those studies using the caudal route of administration injected higher volumes of solution, which may itself be analgesic. 44 In summary, there is conflicting evidence characterized by a moderate degree of certainty that TF ESIs provide superior benefit to other approaches. 2 For the differences between IL ESI and the caudal approach, the evidence is too scant to draw any conclusions.
The rationale for selection of a particular ESI technique is guided by multiple factors to include radiological evidence of pathology, patient symptoms, previous surgery, demonstrated efficacy, and consideration of possible complications. The distinct advantages and disadvantages of each approach are discussed in the following sections.
CAUDAL
The sacral hiatus provides the most caudad and direct route of entry to the epidural space and allows for the administration of steroid-based solutions for the treatment of lumbar pathology. Caudal ESIs are less targeted than either TF or IL approach in that the site of injection is not altered according to the level of pathology. Advantages of the caudal approach include a dramatically decreased incidence of dural puncture given the distance from the thecal sac, their safety in postsurgical patients who are at higher risk for both dural puncture and neurological complications related to the intravascular injection of particulate steroids, and possible increased prevalence of ventral epidural spread related to the higher volumes utilized. 68 Meta-analyses have provided conflicting results regarding the role of caudal ESIs in several pain conditions. Several systematic reviews have shown good (level I) evidence for both short-and long-term benefit in managing back and leg pain due to disk herniation, similar (level I) evidence for treating discogenic pain, and less compelling evidence for treating pain associated with spine surgery (level II-2) or spinal stenosis (level II-1).
68Y70
In addition, many practitioners use the caudal route to insert a catheter, which can then be guided up to the targeted area of pathology. When epidural lysis of adhesions is performed, most studies have utilized a caudal catheter-guided approach. In a systematic review by Racz et al, 71 the authors concluded there was strong evidence to support both short-and long-term relief with epidural lysis of adhesions, when repeated interventions are permitted. For lumbar herniated disk, the evidence was moderate for short-and long-term improvement. Of note, most, 72 herniation and previous surgery and carry an extremely low risk of inadvertent dural puncture.
INTERLAMINAR
Interlaminar ESI can be performed at all levels of the spine and involve passage of a needle through the ligamentum flavum to deliver medication. Similar to caudal ESIs, IL ESIs have been studied extensively regarding their role in radicular pain due to disk herniation, pain due to spinal stenosis, axial back pain in the absence of disk herniation, and failed back surgery syndrome. In addition, IL ESIs have also been studied in pain conditions involving the thoracic and cervical spine. Advantages of this technique include the increased likelihood that injected medication will reach adjacent spinal levels, the ability to treat bilateral pain, and the need for a lower volume of medication when compared with caudal ESIs. Disadvantages include the potential for dural puncture and deposition of medication into the dorsal epidural space, which is more distant from the site of pathology, although 1 prospective study demonstrated a 100% incidence of ventral epidural flow using a parasagittal IL approach. 56 
Lumbar Interlaminar
Regardless of whether they have excluded studies in which IL ESIs were performed blindly, systematic reviews of IL ESIs in the lumbar region have yielded similar results. On balance, there appears to be good evidence for the treatment of radicular pain due to disk herniation and somewhat weaker evidence for treatment of spinal stenosis, discogenic pain, and postsurgical pain. 75Y77 However, there is some diversity in the literature as is evidenced by some reviews that conclude there is good evidence for treating spinal stenosis, 78 whereas others show an unclear benefit for all conditions to include radicular pain.
79,80
Thoracic Interlaminar
Pain arising from the thoracic region of the spine is less prevalent than pain in either the neck or low back. 81, 82 Thoracic IL ESIs are therefore less commonly performed than either the lumbar or cervical approaches and consequently have been less studied. In addition to spinal pain, there is strong evidence (level I) to support the use of intrathecal steroids for postherpetic neuralgia (PHN), and moderate evidence in favor of the early use of ESI in acute herpes zoster to prevent PHN. 83 For the latter, a randomized controlled study demonstrated a decreased incidence of PHN in patients with acute zoster who received ESI compared with a control group who received parenteral acyclovir and steroids, 84 whereas a similarly designed study demonstrated a lower incidence at 1 month, but not 3 or 6 months after injection. 85 The sole review on the subject notes the paucity of literature but does report fair evidence for treatment of both pain due to thoracic disk herniation and disk degeneration. 86 
Cervical Interlaminar
Systematic reviews of cervical IL ESIs have provided mixed evidence for their use in treating cervical radicular pain. Reviews published by the American Society of Interventional Pain Physicians conclude there is good evidence for radiculopathy secondary to a herniated disk (level I), and fair evidence for spinal stenosis, discogenic pain, and failed neck surgery syndrome (level II-1). 87, 88 An evidence-informed review by Stout 89 concluded that cervical ESIs are probably effective in the short term, but that definitive evidence is lacking. The author further noted that the evidence is stronger for herniated disk and nonosseous central stenosis than it is for foraminal or osseous stenosis and that ESI should not be a first-line treatment. Another evidence-informed review by a surgical task force found that cervical ESIs are probably effective for cervical radicular pain in the short term, but that evidence supporting long-term relief is lacking. 90 Overall, the bulk of recent evidence supports a primary indication for lumbar, thoracic, or cervical IL ESIs of radicular pain due to disk herniation. In the lumbosacral region, the IL approach should be considered in patients with bilateral symptoms or multiple affected spinal levels who have not had spinal surgery. In light of the increased risk for complications stemming from TF ESI performed in the upper lumbar, thoracic, or cervical regions, IL ESI should always be the first-line injection treatment in these areas.
TRANSFORAMINAL
Similar to IL ESI, the TF epidural approach can be utilized in lumbar, thoracic, and cervical spinal levels, but unlike the IL technique, it can also be performed at sacral levels. The TF injection technique involves the placement of a needle within a neuroforamen, does not require a loss-of-resistance technique, and must be performed with fluoroscopic guidance. The TF approach has several theoretical advantages over other routes of injection in that it is the most target-specific, carries a lower risk of inadvertent dural puncture, 91 and is associated with a greater incidence of ventral epidural spread, especially with placement of the needle in the anterior foramen. 92 However, TF ESIs are also associated with an increased risk profile compared with the caudal and IL approaches. In addition, although there is some evidence for better efficacy compared with caudal and IL ESI, 93 their efficacy in neuropathic spinal pain (NSP) still remains controversial.
Lumbar Transforaminal
Systematic reviews are hampered by significant heterogeneity but have generally found good evidence supporting short-term relief and mixed evidence in favor of long-term benefit for TF ESIs in treating back pain with radicular symptoms due to disk herniation. 94Y96 One recent review found good evidence for the treatment of radicular pain secondary to disk herniation, but only fair or limited evidence for the treatment of spinal stenosis, postsurgical pain, or axial pain in the absence of disk herniation. 97 Reviews dedicated specifically to either spinal stenosis or postsurgical pain are lacking. Subgroup analyses in several clinical studies have shown either comparable benefit in patients with herniated disk and spinal stenosis 63, 98 or only a small benefit in favor of herniated disk. 99 In a comprehensive review by members of the International Spinal Intervention Society (ISIS), the authors concluded that a ''substantial proportion'' of patients with lumbar radicular pain caused by a contained disk herniation will experience an improvement in pain, function, decreased health care utilization, and a reduced need for surgery following treatment with TF ESI. They found that the evidence was stronger for treating a herniated disk(s) than for spinal stenosis and that the evidence was more compelling when all of the published data were considered than if only a systematic review evaluating RCTs was performed. 100 
Cervical and Thoracic Transforaminal
The TF approaches to the cervical and thoracic spine are less studied than their lumbar counterpart, and the literature abounds with case reports and reviews detailing the potentially catastrophic complications associated with these approaches.
101Y103
Systematic reviews are lacking, and available studies are mostly of the nonrandomized or retrospective variety.
The lone randomized, controlled study for the cervical approach showed positive results in patients with radicular pain, but lacked a pure placebo group. 104 Multiple nonrandomized studies have shown both short-term 105 and long-term benefits with single and repeat injections 106Y108 in treating cervical radiculopathy. Among all injection types, TF thoracic ESIs are the least represented in the literature. One large retrospective study showed a high rate of short-term pain relief (88.5%) but was primarily designed to investigate complication rates and included patients with diverse pain complaints to include disk herniation, spondylosis, spinal stenosis, postsurgical pain, and degenerative disk disease. 109 Overall, the literature suggests that although the TF approach may be more efficacious than the IL or caudal approaches, the difference in effect size is small. In the cervical, thoracic, and midlumbar to high lumbar regions, the increased risk for catastrophic neurological complications should preclude the use of TF ESI as a first-line treatment. 110, 111 In the lumbar region, TF may be considered as a first-line treatment in patients with a history of back surgery who are at increased risk for postdural puncture or who possess focal pathology with correlating unilateral symptoms, although prior surgery may increase the likelihood of intravascular injection.
EFFECT OF REGION
The region of injection for ESI may influence outcomes, with the 3 primary sites consisting of the cervical, thoracic, and lumbar areas. For cervical ESI, a best-evidence synthesis by Carragee et al 90 found support for short-term improvement of radicular symptoms, whereas a narrative review by Huston 112 concluded that although pathophysiological studies supported the use of cervical ESI, more RCTs were needed to evaluate effectiveness. Since publication of these reviews, 3 RCTs failing to show benefit have been published by the same group of investigators.
113Y115 To date, only 1 randomized clinical trial evaluating thoracic ESI has been published, which found no significant difference between epidural steroids and epidural local anesthetic, with both groups demonstrating significant improvement through 12-month follow-up. 116 However, anecdotal reports suggest comparable benefit for lumbar and cervical procedures. 117 The lumbar region represents the focus of most of the ESI region-specific literature, with the strength of evidence found in systematic reviews growing over recent years. Some reviews found a lack of evidence to support lumbar ESI due to myriad limitations including poor study quality, 118 poor technical quality of injections, 75 and inclusion of non-ESI injection therapy in the analyses. 80 In contrast, most recent systematic reviews of lumbar ESI report positive findings, from fair to good evidence, 76 ,96 level 1 evidence, 68 level II-1 and II-2 evidence, 68, 94 and moderate evidence. 119 
EFFECT OF CONTROL GROUP
Efficacy of ESI depends in part on the type of control injection used for comparison. Epidural steroid injection ''control groups'' in the literature include epidural saline or local anesthetic injections (epidural nonsteroid) and intramuscular or ligamentous injections of corticosteroid, local anesthetic, or saline (nonepidural injection). In indirect comparisons, epidural nonsteroid injections have been demonstrated to provide superior benefit compared with nonepidural injections on at least some outcome measures. 120 This observation is not unique to epidural treatment but is conjectured to be applicable to other therapeutic injections as well. 121 Hence, when a control group consists of epidural nonsteroid injections instead of nonepidural injections (ie, a comparative-effectiveness study), because in essence 2 treatments are being compared (rather than a treatment and a placebo), more patients are needed to detect a difference. This suggests that a large proportion of clinical trials evaluating ESI were underpowered.
EFFECT OF DOSE AND INJECTATE
Characteristics of the injectate also differ among studies and may impact patient outcome as shown in Table 4 . Both the dose and volume of steroid may vary depending on the route of injection, with amounts of each typically increasing as TF, IL, and caudal ESI are performed, respectively. The effect of the dose of steroid for ESI has been examined in 2 randomized studies. In the first study by Owlia et al, 122 an IL ESI dose of 40 mg of methylprednisolone provided a similar reduction in pain with fewer adverse effects compared with 80 mg. A second randomized, double-blind study by Kang et al 123 evaluating the effect of steroid dose during TF ESI found no differences in efficacy between triamcinolone doses of 10, 20, and 40 mg, although 5 mg failed to provide a similar level of benefit.
As alluded to earlier, Rabinovitch et al 44 concluded there was an independent, beneficial effect for volume, as the use of higher volumes may result in pain relief in and of itself. A randomized study by Revel et al 124 found that steroid injected in a volume of 40 mL of saline provided superior pain relief than when the same dose of steroid was injected by itself at 18 months' follow-up.
EFFECT OF TYPE OF STEROID
Data evaluating different types of steroid injections are mostly limited to underpowered randomized or retrospective studies comparing particulate to nonparticulate steroids. Among the 3 randomized comparative-effectiveness studies comparing different steroid preparations, 2 reported a nonsignificant benefit in favor of the depo-steroid group, 125, 126 with only the largest finding a statistically significant difference for depo-steroids. In the 3 retrospective studies, one found depot steroids was statistically better than nonYdepo-steroids, 128 one showed a trend toward superiority for depo-steroids over non-depot steroids in patients with cervical radiculopathy, 105 and another found no difference between depo-and nonYdepo-steroids for cervical TF ESI. 129 In summary, there is conflicting evidence with a low degree of certainty that depo-steroids provide superior relief compared with nondepot steroids. 2 
EFFECT OF UNDERLYING PATHOLOGY
The efficacy of ESI varies in accordance with the underlying pathology causing NSP. The numerous and diverse conditions that result in spinal pain mandate the use of stringent inclusion criteria for ESI studies to provide clinically meaningful information regarding efficacy, although studies seeking to determine effectiveness may utilize more pragmatic selection criteria that reflect clinical practice. Lumbar herniated nucleus pulposus (HNP) represents the most commonly studied condition, with the most recent and comprehensive systematic reviews demonstrating good 76 and level I 68 evidence supporting the role of ESI, particularly for short-term relief of pain. For intermediate-and long-term benefit (93 months), the benefit is significantly smaller and may well represent the effect of disease evolution. 130, 131 A more limited set of evidence exists for the effectiveness of ESI for other pathology. Some reviews have reported that the evidence for ESI in spinal stenosis is less robust than for herniated disk, but greater than that for failed back surgery syndrome and axial back pain. 97, 132, 133 However, in clinical studies and subgroup analyses from placebo-controlled trials, some 60,99,134,135 but not all 63, 98, 136, 137 studies have demonstrated better results for herniated disk than spinal stenosis. In a study that sought to identify radiological outcome predictors for cervical ESI, those patients with central stenosis experienced greater benefit than individuals with herniated disk, neuroforaminal stenosis, or nerve root compression. 138 
EFFECT OF SPECIALTY
The influence that the medical specialty of the investigators has in both the interpretation of existing data (ie, systematic reviews) and on the generation of data (ie, results of clinical trials) is extensive. Studies performed by interventionalists are approximately 3 times more likely to report a positive result than those conducted by noninterventionalists. For the evaluation of clinical trials in the form of review articles, the discrepancy is both more pronounced and difficult to reconcile, as different groups evaluating the same data using the same or similar methodological rating schemes have reached different conclusions. There are multiple reasons for these inconsistencies, which include confirmation bias, 139 dissemination bias (ie, publication bias for specialty journals and selective reporting), 140 a better ability of specialists to evaluate selection criteria and technical proficiency, and perhaps even secondary gain ( Fig. 3 and Table 5 ).
IDEAL NUMBER OF INJECTIONS
There are no clinical trials examining the ideal number of ESI. Numerous guidelines have determined that there is no basis to perform a set series of repeated injections without regard to response, but rather that the number of ESI should be individually tailored to clinical response. 141Y143 Novak and Nemeth 144 performed a literature review in an effort to determine the ideal frequency and timing of ESI. They found that although repeat injections tended to be the norm, there was no evidence to support the practice of a routine series of injections. However, the strategic use of repeat injections may enhance outcomes in certain contexts. In a narrative review by Roberts et al, 96 the authors noted that among the 4 level I (randomized controlled) studies evaluated, the 2 that allowed for more than 1 injection reported positive outcomes, 55, 136 whereas the 2 studies that limited the number of injections to 1 injection reported negative outcomes. 145, 146 The guidelines published by the American Academy of Physical Medicine and Rehabilitation and ISIS both state that if additional injections are warranted, they should be separated by at least a 2-week interval to enable assessment of the full response and to minimize adverse effects such as adrenal suppression. 141, 142 In a comprehensive review by MacVicar et al, 100 the authors found that 94% of patients achieve a successful outcome after 1 injection, with only 4% of individuals requiring more than 1 treatment.
COMPARATIVE-EFFECTIVENESS STUDIES
There have been few comparative-effectiveness studies comparing ESI to other treatments, and only 1 in which patients were purportedly blinded. In an underpowered 6-month study by Koc et al, 147 the authors randomized 29 patients with lumbar spinal stenosis to receive either a high-volume ESI, 2 weeks of physical therapy, or a control group that received no treatment. At follow-up, all groups improved in most measures, with the only statistically significant differences being noted at 2 weeks between the ESI and noninjection groups for pain and function.
In a similar study by Laiq et al, 148 the authors randomized 50 patients with lumbar spinal stenosis to receive either Study stratification based on primary author specialty, with anesthesiology or physical medicine and rehabilitation representing pain physicians, and all other specialties representing nonpain physicians. Benefit tabulated at initial visit for primary outcome measure. Percentage of positive ESI studies and review articles stratified by specialty based on first author affiliation. When multiple controlled studies were performed by the same group of authors reported the same results (ie, Manchikanti et al 184, 186, 191 ), only one from each category was counted (eg, 1 negative caudal, 1 negative lumbar IL, and 1 negative cervical IL injection).
high-volume ESI or conservative treatment with bed rest, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and opioids. Although the steroid group experienced greater pain relief and higher satisfaction scores at 2 weeks and 1 month, no significant differences were noted at later time points. When evaluating the 1-month data, a significant flaw that needs to be considered is that the conservative group received suboptimal noninterventional treatment, as neither bed rest nor NSAIDs or 149 Whereas opioids may provide short-term relief, only a small proportion of individuals will experience long-term benefit. 150 In the only double-blind, comparative-effectiveness study evaluating ESI, Brown 151 
Both groups improved, with the decrease in leg pain, but not back pain, reaching statistical significance in favor of the surgery group through 6 months. After 6 months, no differences were noted between groups. Whereas 27 patients who received the ESI crossed over to surgery, 46% did not, suggesting a surgery-sparing effect.
Overall, these findings are consistent with systematic reviews that have found at least moderate evidence for short-term but inconsistent evidence supporting long-term benefit. 90, 130, 131 Another factor that must be considered when evaluating openlabel comparative-effectiveness studies is that the placebo response rate is likely to be significantly higher for injections than it is for noninterventional therapies. 154 
COST-EFFECTIVENESS
In the current era characterized by the need to alter the trajectory of rapidly ascending health care costs, the costeffectiveness of any intervention has assumed an increasingly important role. The cost-effectiveness of any intervention is heavily dependent on utilization patterns and selection criteria. Selecting patients for any interventional procedure characterized by a modest likelihood of success without proper screening (ie, performing ESI on all patients with back pain) is likely to tip any cost-benefit analysis in the direction of costs, while withholding a relatively safe and inexpensive treatment that might facilitate return to work or prevent surgery, can reduce cost-effectiveness. The likelihood of returning to work full-time declines nearly exponentially with time in patients with new onset of back pain with or without radicular pain, and those remaining out of work for more than 3 months are unlikely to return to work regardless of the intervention. 155 Consequently, core domain outcome measures for chronic pain, as identified by a multidisciplinary group of academic, industry, and governmentdesignated specialists, do not even include return to work as a potentially achievable outcome. 156 Because of the high costs of surgery, health care utilization, disability, and lost productivity, any cost-benefit analysis for ESI is to a large extent contingent on reducing alternative health care utilization (eg, surgery and health care provider visits) and expediting or enhancing return to work.
PREVENTION OF SURGERY
One outcome that can greatly affect the balance of the costeffectiveness analysis of any intervention is the need for surgery.
Even for neuropathic pain, the surgical rate and the proportion of spine surgeries requiring fusion or instrumentation are higher in the United States than in any other country. 157, 158 In largescale epidemiological studies, a direct correlation between spine surgery rates and ESI has been found, 159 although this is likely attributable to resource utilization patterns.
There has only been 1 randomized study evaluating the ability of ESI to affect surgery rate as a primary outcome. 136 In a double-blind study, an orthopedic spine group compared the operative rate in patients with herniated disk or spinal stenosis who were randomized to receive a series of either lumbar TF ESI or epidural bupivacaine. At follow-up periods ranging between 13 and 28 months, 29% of patients in the treatment group underwent surgery, which favorably compared with a 67% operative rate in the control group. At subsequent 5-year follow-up, most patients who had avoided surgery for the initial year continued to avoid surgery. 160 All 8 patients lost to follow-up at 5 years who had initially avoided surgery received TF ESI, making comparisons at that time interval difficult. In another randomized study by an orthopedic spine group, Rasmussen et al 161 found that that ESI performed after surgery enhanced recovery, decreased hospital stay, and reduced postoperative neurological impairment for up to 2 years following diskectomy for HNP, although no difference in reoperation rates was noted. In an analysis of data from the multicenter, randomized SPORT study comparing surgery to nonsurgical treatment for herniated disk, fewer patients who received ESI within 3 months of enrollment expressed a preference for surgery (19% vs 56%), and a higher percentage crossed over from surgical to nonsurgical management (41% vs 12%), than those who did not receive ESI. 162 For a subgroup analysis performed in patients with spinal stenosis, conflicting findings were noted. Among those patients who received ESI during the first 3 months of enrollment, more patients expressed a preference for nonsurgical treatment (62% vs 33%), and a higher percentage allocated to surgery crossed over to the nonsurgical care (33% vs 11%), than those individuals who were not treated with ESI. 163 However, in the nonsurgical group, more patients who received an ESI crossed over to surgery than those who did not (58% vs 32%). Along with the controlled studies, several uncontrolled studies performed by spine surgeons evaluating surgery as a primary outcome measure have also found a surgery-sparing effect for ESI. 164, 165 In contrast, the large majority of randomized controlled studies evaluating surgery rates as a secondary outcome measure failed to find a difference in operative rates between ESI and placebo treatment, 99, 137,145,146,166Y178 compared with the few that did. 179, 180 The difficulty in evaluating surgery rates as a secondary outcome is that nearly all studies are underpowered to detect a difference and incorporate some degree of bias through patient selection. Many patients who receive ESI are either poor surgical candidates or do not want surgery, so that even an effective treatment may not be able to demonstrate a decrease in surgery rates. Others who are referred from surgery for a temporizing intervention and do have serious surgically amenable pathology may be on a predestined course in which operative treatment is a foregone conclusion. To be able to detect a difference in operative rates and reduce bias, one needs patients with surgically treatable pathology, who are considering surgery but would prefer a less invasive treatment option. The ideal setting to recruit such patients would be a spine surgery center, where the operative criteria can be standardized, and an effective intervention has a reasonable chance to alter the decision-making process. It is not surprising then that the studies suggesting ESI can prevent surgery have been performed by surgeons.
RETURN TO WORK
There are several obstacles in evaluating return-to-work data, with the major one being the extremely low likelihood of anyone who has been out of work for more than 1 year returning to work full-time. Nevertheless, several investigators have evaluated either return to work or missed work days as a secondary outcome, which in essence means all studies have been underpowered to detect a difference. Not surprisingly, a majority of clinical trials have failed to report a significant difference between return-to-work rates or missed work days when ESI and control groups are compared. 146, 166, 167, 178, 179 Yet, some studies suggest that in well-selected patients, ESI may improve work status. More patients returned to work in the ESI group than in the control group in several randomized studies (63% vs 25% in Breivik et al, 181 54% vs 40% in Kraemer et al, 174 and 53% vs 33% in Rogers et al 182 ), although all are limited by the small number of participants. In a large-scale (n = 228), double-blind, placebo-controlled cost-effectiveness health care assessment on the efficacy of ESI, Price et al 169 found no significant difference in the proportion of subjects unable to return to work 1 year after treatment (24.1% in the treatment group vs 22.2% in the control group), although the mean number of days the treatment group missed work because of radiculopathy declined more than the number of days in the control group (j65 vs j33).
HEALTHCARE UTILIZATION
Beyond the need for surgery and return to work, further evaluation of health care utilization following ESI results in few direct measurements, and to date, an advanced search of The Cochrane Library yields no relevant economic evaluations of ESI. 183 Investigators looking for a reduction in opioid intake following ESI have met with mixed results, as both ESI and control injections typically result in a decline in analgesic intake. 86 When controlling for diagnosis, randomized comparativeeffectiveness studies have found that ESIs reduce opioid intake for within-group but not between-group comparisons in patients suffering from HD with radiculitis, 184, 185 failed back surgery syndrome, 114, 186 discogenic spine pain, 187, 188 and lumbosacral spinal stenosis.
189Y191 Studies evaluating the ability of ESI to reduce health care utilization as a secondary outcome measure have also yielded conflicting results. A randomized controlled study by Karppinen et al 146 found no overall difference in health care costs between treatment and control groups, although the steroid group had lower medication and therapy costs at 4-week follow-up. Similar secondary analyses of other controlled studies have found either no difference 166, 167, 179 or only small, nonsignificant differences 168 in the utilization of other treatments. The economic analysis of a large, randomized trial by Price and colleagues 169 concluded that ESIs do not provide good economic value in as much as the cost per quality-adjusted lifeyear for the treatment from the perspective of both the provider and purchaser exceeds the implied thresholds outlined in the National Institute for Health and Clinical Excellence technology appraisal. These findings are consistent with a cost-minimization analysis performed by Straus, 192 which concluded that unlike spinal cord stimulation, ESIs performed under fluoroscopy may not be justified. To date, no studies have directly measured cost utilization outcomes in association with ESI in a controlled fashion. However, extrapolation of an indirect analysis showing that patients with neuropathic pain (44% of whom had radiculopathy) who were managed primarily in pain clinics had significantly fewer emergency room and doctor visits and lower hospitalization costs, compared with those managed by primary care providers or other specialists, suggests that procedural interventions could reduce health care utilization when appropriately utilized. 193 Further studies aimed at evaluating costeffectiveness not only for ESIs but also for other procedures are warranted.
FACTORS ASSOCIATED WITH
TREATMENT OUTCOME
General Factors
In view of the discrepancies between clinical experience and clinical trials, as well as the obstacles faced when designing efficacy studies evaluating ESI, clinicians and researchers have turned their attention toward identifying predictive factors associated with both NSP and ESI outcomes. Although daunting, if NSP patients could be stratified according to phenotypic variables linked to positive (and negative) outcomes following a trial of ESI, treatment could be better tailored to enhance efficacy and cost-effectiveness. A wealth of clinical and experimental data is emerging, but its interpretation remains difficult.
Neuropathic spinal pain is a challenging condition for both primary care providers and specialists in that treatment outcomes are often disappointing, 194, 195 even in light of attempts to develop a more focused therapeutic approach. 196, 197 Part of this difficulty arises from the general nature of the umbrella term ''neuropathic pain,'' with different recommendations having been issued for different subsets of patients. 198 Even within specific diagnostic categories, substantial predictive variability persists. This variability likely results from the heterogeneity of neuropathic pain mechanisms, concomitant pain generators, and coexisting psychosocial issues. 199 In patients with NSP, important predictors of outcome include age, measures of disease burden, socioeconomic factors (eg, job satisfaction), and psychopathology. Not only is there a higher risk of developing NSP with increasing age, but older patients tend to experience worse outcomes than their younger counterparts. 200 Proposed explanations for this phenomenon include a greater likelihood of comorbidities, multiple pain generators, and polypharmacy. 201 This effect is independent but amplified by the possible lower degree of efficacy for ESI in spinal stenosis compared with herniated disk. 93, 97 Because of the increased risk for adverse pharmacological effects in this cohort, an argument can be made for interventional therapy.
High disease burden is another important marker of poor outcomes in both back and neck pain patients. 202Y204 Indirect measurements of increased disease burden include higher baseline pain scores and disability, 149, 205 greater use of opioids, 206, 207 and a history of failed interventions, 208, 209 which have all been shown to be prognosticators of poor outcomes in patients with back and neck pain. Patients with lower levels of education and lack of employment at time of diagnosis may also have worse outcomes than those in higher socioeconomic groups. Along with a lower financial incentive to return to work, it is theorized that patients in lower socioeconomic brackets may also have less access to routine health care surveillance and often present only after a disease process has significantly progressed past the ideal therapeutic window, at which time the likelihood of treatment success has decreased. 210 Many studies have documented a high coprevalence rate of psychopathology with neck and back pain, 211Y212 and depression and other forms of psychological distress are negative prognosticators in patients with chronic pain of all types, including NSP. 213Y216 In addition to depression, poor coping mechanisms, catastrophization, somatization traits, secondary gain, and the presence of Waddell signs have also been shown to predict treatment failure.
211,216Y219
Factors Associated With ESI Results
Not surprisingly, disease burden and the presence of coexisting psychosocial stressors have been consistently found to portend negative treatment outcomes after ESI. A study by Jamison et al 220 found the predictors of treatment failure 2 weeks after ESI included a greater number of previous failed treatments, higher analgesic use, unrelenting pain not worsened by activity, and pain increased by coughing. One year after treatment, unemployment secondary to pain, poor response to analgesics, negative straight-leg-raising test, and pain unaffected by activities were associated with negative treatment outcomes. A prospective cohort study by Hopwood and Abram 221 performed in 209 patients who underwent lumbar IL ESI found that constant pain, prolonged duration of pain, smoking, unemployment, sleep dysfunction, psychological distress, and nonradicular pain were associated with treatment failure in univariate analysis. After logistical regression analysis, only prolonged duration, nonradicular pain, lack of employment, and smoking remained significant predictive factors. The negative correlation between symptom duration and treatment response is supported by other studies. 98 A recent study by Kirpalani and Mitra 222 found 70% of opioid-naive patients had a positive outcome after cervical ESI, compared with only 20% in patients on chronic opioid therapy.
Another predictive factor for ESI success is the nature of a patient's symptoms. 87 Systematic reviews 97, 132, 133 and studies performed in the cervical 223 and lumbar 76 spine have generally found that radicular pain is more responsive than axial pain secondary to mechanical pathology. When broken down by etiology, some studies suggest that a herniated disk may respond better to ESI than neurogenic claudication secondary to spinal stenosis, 60,99,134,135 although this finding is by no means universal. 63, 98, 136, 137 Even in patients with a particular diagnosis, the severity and subtype of pathology may affect outcome. Among individuals with spinal stenosis, a direct correlation has been found between the severity of pathology and response to treatment. 138, 224 In a subgroup analysis of a randomized, placebo-controlled study by Ghahreman and Bogduk 170 performed in patients with herniated disk, the authors noted an inverse relationship between the degree of nerve root compression on magnetic resonance imaging and the likelihood of a successful outcome. This association was hypothesized to stem from the fact that those with low-grade compression experienced predominantly inflammatory-mediated pain, as opposed to pain due to mechanical compression that is more refractory to treatment. Other studies have yielded mixed results regarding an association between ESI outcomes and the extent of degenerative end-plate spinal changes. 225, 226 Finally, several investigators have sought to identify prognostic factors for ESI based on their preinjection response to standardized sensory testing. In a small study by Schiff and Eisenberg, 227 the authors reported mixed results for the ability of quantitative sensory testing to predict the response to ESI, with a direct correlation being noted between improvement in pain scores and increase in cold sensation threshold but an inverse correlation between pain score improvement and increase in touch and vibration thresholds, mediated by A-beta fibers. Given the expense and time associated with performing baseline quantitative sensory testing, the mixed results do not currently support this practice. In an attempt to find a simpler and more practical means to determine whether intrinsic sensory perception can predict ESI outcome, Cohen et al 228 found a small but statistically significant correlation between the perceived intensity of the pain response to a standardized subcutaneous injection of local anesthetic immediately before a set of ESIs and a person's response to the injections, which persisted through 3-month follow-up. In summary, the weak and often conflicting association between baseline demographic and clinical factors and response to ESI, and the low risks associated with the procedure, make screening out potential candidates with NSP based on phenotypic characteristics impractical at this time (Fig. 4) .
Complications
Complications associated with the epidural administration of corticosteroids are uncommon, but their risk has been highlighted by the recent and devastating outbreak of fungal meningitis in the United States. 229 Following epidural administration of contaminated steroid, more than 650 cases of fungal infection and 39 deaths were reported in late 2012. There is no mandatory reporting of complications in the United States, and thus the true incidence of serious adverse effects and complications associated with epidural administration of corticosteroids cannot be determined. Despite warnings about the neurotoxic potential of intrathecal injection of corticosteroids, 230 there are few reports of serious complications associated with epidural administration.
A recent retrospective study examined 4265 ESIs performed in 1857 patients over 7 years, which included 161 cervical IL injections, 123 lumbar IL injections, 17 caudal injections, and 3964 lumbar TF injections. 91 No major complications were identified. There were 103 minor complications, for an overall complication per injection rate of 2.4%. The most common complications were increased pain (1.1%), pain at the injection site (0.33%), persistent numbness (0.14%), and ''other'' (0.80%).
Complications were less common with TF injections (2.1%) than for IL injections (6.0%). The American Society of Anesthesiologists Closed Claims Study provides some insight into less common major complications, reporting on 114 complications purportedly caused by ESIs that resulted in malpractice litigation. 231 The types of complications cited in that report are shown in Table 6 . Complications that have been reported following epidural corticosteroid injections include neurotoxicity, neurologic injury, pharmacological effects of corticosteroids, and other less frequent problems. The aim of this section is to review our current knowledge regarding the complications associated with ESI.
Neurotoxicity
Direct neurotoxicity caused by the unintentional intrathecal injection of corticosteroid suspensions has been hypothesized to result in arachnoiditis and aseptic meningitis in some individuals. However, the link between intrathecal corticosteroid administration and these neurotoxic syndromes is not at all clear. Arachnoiditis is an inflammatory condition involving the leptomeninges and the underlying neural structures. 232 Commonly encountered symptoms include constant, burning pain in the lower back and legs; urinary frequency, incontinence; muscle spasms in the back and legs; variable sensory loss; and motor dysfunction. Adhesive arachnoiditis is a severe and often progressive form that is associated with neuropathic pain and neurologic dysfunction. The intrathecal injection of neurotoxic substances can result in arachnoiditis if there is sufficient chemical irritation or inflammation. Aseptic meningitis is a generally benign condition that produces signs of neurological irritation, including burning pain in the legs, headache, meningismus, and in severe cases seizures. Fever and nausea are often reported. Cerebrospinal fluid examination reveals pleocytosis, elevated protein, and decreased glucose. The introduction of nearly any substance, including blood, normal saline, or water, into the subarachnoid space can potentially produce the syndrome. 233 The first reported cases of arachnoiditis followed neuraxial syphilis or tuberculosis infections. Iatrogenic arachnoiditis was first reported after intrathecal injection of oil-based radiographic contrast agents. Arachnoiditis is most commonly diagnosed among patients who have had multiple prior spinal surgeries, so that identifying the inciting cause is difficult. Arachnoiditis is an uncommon condition, and the symptoms are often difficult to separate from those for which many patients receive ESI. Concern regarding the neurotoxic potential of corticosteroid suspensions arose during treatment of advanced cases of multiple sclerosis (MS) with intrathecal methylprednisolone acetate (MPA). The earliest report of arachnoiditis following intrathecal steroid injections cited 2 cases of adhesive arachnoiditis among a series of 23 patients who received a total of 83 injections of MPA. 234 The author of that report expressed concern that the drug vehicle, polyethylene glycol, could have initiated the inflammatory response. Additional, sporadic case reports have appeared in which individual patients developed arachnoiditis after intrathecal administration of multiple doses of corticosteroids to treat advanced MS. 235, 236 A single case of myelographically documented arachnoiditis has been reported following intrathecal MPA treatment for lumbar disk disease 237 ; the intrathecal injection occurred in conjunction with inadvertent dural puncture during attempted epidural administration.
Seghal et al 238 documented the occurrence of aseptic meningitis following intrathecal injections of 40 to 200 mg MPA, whereas Goldstein et al 239 were unable to show any cerebrospinal fluid changes or symptoms of meningeal irritation in patients with MS treated with 40 mg MPA. Several cases of aseptic meningitis have also been reported following intrathecal corticosteroid injections.
240Y242 One of these cases was severe, producing headache, fever, nausea, bilateral leg pain, and seizures. 240 One case of aseptic meningitis was reported following an epidural injection of MPA. 243 A recent study of intrathecal MPA for PHN failed to find any evidence of either aseptic meningitis or arachnoiditis among 89 patients treated with four 60-mg injections. 244 Patients were followed up for 2 years and underwent diagnostic lumbar punctures and magnetic resonance imaging.
It is difficult to determine which component of the steroid preparation, if any, is neurotoxic. Nelson 230 suggested that polyethylene glycol is the offending agent. This speculation was based on studies demonstrating that concentrations of propylene glycol 78% or greater cause nerve injury. 245, 246 The polyethylene glycol preparation used in steroid suspensions is present in concentrations of 2.8% to 3%. Benzon et al 247 studied the acute effects of polyethylene glycol on nerve conduction and found no changes with concentrations of 3% and 10%, slowing of conduction with 20% and 30%, and abolishment of conduction with 40%; the effects were reversible following washout. Benzyl alcohol 0.9% is present in several steroid suspension preparations, including multidose vials of Depo-Medrol brand MPA (Pharmacia & Upjohn, Kalamazoo, Michigan) and Aristocort Intralesional brand triamcinolone diacetate (American Cyanamid, Madison, New Jersey). Two animal studies reported no or minimal histological changes following the neuraxial injection of the triamcinolone/benzyl alcohol preparation, 248, 249 although the clinical relevance of this remains unknown. There have been reports of aseptic meningitis following intracisternal injections of pyrogen-free serum albumen plus 0.9% benzyl alcohol. 250 Following up in these reports, Deland 251 assessed the effects of intracisternal injections of benzyl alcohol 0.9% to 9% in dogs. The highest concentration (10 times the concentration used as a preservative in pharmaceutical agents) produced transient neurological dysfunction related to local anesthetic effects, but there was no evidence of aseptic meningitis at any concentration. Few 231 (2004) histological abnormalities were noted, and those that did occur were observed as frequently in saline controls. There was considerable public controversy about the risk of arachnoiditis following epidural MPA injection during the 1990s in Australia, prompting many physicians to use Celestone Chronodose (Schering-Plough, Kenilworth, New Jersey) for ESI. This product contains betamethasone 5.7 mg, as betamethasone sodium phosphate 3.9 mg (in solution), and betamethasone acetate 3 mg (in suspension) per milliliter in an aqueous vehicle containing sodium phosphate, sodium phosphate monobasic, disodium edetate, benzalkonium chloride, and water. Despite the absence of both polyethylene glycol and benzyl alcohol in this solution, a study in sheep demonstrated the development of histopathologic changes of arachnoiditis following intrathecal injection of 2 mL or more of this preparation. 252 The product is available in the United States as Celestone Soluspan (Schering-Plough).
It is not clear whether a single intrathecal injection is likely to cause serious harm. The reported cases of arachnoiditis were associated with multiple intrathecal injections, and in most cases there was preexisting neurologic disease. Arachnoiditis and aseptic meningitis are complications of intrathecal, not epidural, steroid injections. The use of a local anesthetic test dose and/or fluoroscopy and radiographic contrast are reliable means to prevent unintentional intrathecal administration. There is no definitive treatment for arachnoiditis or aseptic meningitis, with symptomatic treatment and reassurance being cornerstones of therapy.
Neurologic Injury
In the Closed Claims Study, nerve injury occurred in 14 patients following ESI. 231 Six of these resulted in paraplegia, one in quadriplegia. Spinal cord damage can occur from needle entry into the cord. In a recent follow-up analysis, the Closed Claims Study Group examined claims associated with procedures conducted at the level of the cervical spine. 253 Injuries related to cervical interventional pain treatment were often severe and related to direct needle trauma to the spinal cord. Traumatic spinal cord injury was more common in patients who received sedation or general anesthesia, especially in those who were unresponsive during the procedure. The majority (59%) of the 64 claims reported in this series were permanent spinal cord injuries related to direct needle trauma to the spinal cord; the most common procedure was epidural injection of corticosteroids. Direct trauma to the spinal cord occurred in association with both the TF and IL routes. Another mechanism of injury is the injection of steroid suspension into a spinal medullary artery with embolization of end arterioles supplying the spinal cord, 254 but this appears to be less common that direct needle trauma to the spinal cord.
The Closed Claims analysis clearly demonstrates that injury to the cord is a significant risk for cervical, thoracic, and upper lumbar epidural injections. Direct needle entry into the cord does not always result in major or permanent neurologic injury. Field et al 255 reported 3 cases of transient neurologic injury that followed otherwise uneventful cervical ESI in awake patients. All 3 patients had large disk herniations that caused effacement of the epidural fat and spinal fluid surrounding the spinal cord at the level of injection. The authors hypothesized that direct injury to the spinal cord or dorsal nerve root could occur even without dural puncture when narrowing or obliteration of the epidural space caused by a large disk herniation displaces the spinal cord posteriorly. More severe neurologic injury occurs if material is injected into the spinal cord, which is more likely to occur in those who are deeply sedated and unresponsive during the procedure. Two cases of spinal cord injury following cervical ESI were reported by Hodges et al. 256 Both cases used fluoroscopic guidance, both cases were performed at C5-6, and in both cases the patient was heavily sedated with a combination of midazolam and propofol. It was postulated that the patients failed to respond to needle contact with the cord because of sedation. In the Closed Claims analysis, among the patients who underwent cervical procedures and experienced spinal cord injuries, 25% were nonresponsive during the procedure, which was significantly higher than the 5% of patients who underwent cervical procedures and did not have spinal cord injuries.
Catastrophic neurologic injury due to embolization of particulate steroid appears to be most common in association with cervical TF injection. This type of injury was implicated in a fatal case of massive cerebellar injury following a cervical TF injection of triamcinolone acetonide. 257 Infarction of the cervical spinal cord resulting in permanent motor and sensory deficits in all extremities following cervical TF injection has also been reported. 254, 258 Similarly, infarction of the lower spinal cord resulting in paraplegia has also been described following thoracic and lumbar TF injections. 259, 260 All of the corticosteroid suspensions commercially available contain particles large enough to occlude capillaries and arterioles. 261 Injection into the vertebral artery can lead to stroke in the posterior circulation of the brain, with cerebellar infarction, cortical blindness, and in some cases death due to resultant intracranial hypertension. Injection into the spinal medullary arteries can result in spinal cord infarction, typically in the distribution of the anterior spinal artery; the magnitude and location of the resultant neurologic injury appear to relate to the anatomic location of injection. Subsequent study in a pig model has conclusively demonstrated that direct injection of particulate steroid into the vertebral artery results in irreversible posterior circulation strokes similar to those reported in case reports following TF injection of steroid. 262 Injection of the nonparticulate steroid solution dexamethasone resulted in no apparent injury in the same animal model, providing preliminary evidence for the safety of this agent. Embolization has not been implicated as a mechanism for injury following caudal or interlaminar ESIs. Although TF injections performed in the lumbar spine carry a much lower risk than in the thoracic or cervical regions, previous surgery may be associated with an increased risk of spinal cord infarct. 111 Spinal cord infarction associated with TF injection is far less common than direct spinal cord trauma according to the Closed Claims analysis. 253 In most cases, there is probably little that can be done to minimize the extent of neurologic dysfunction after a traumatic or embolic event has occurred. High-dose intravenous corticosteroid may be of benefit. High-dose intravenous steroids administered in the hours immediately following traumatic spinal cord injury have been shown to result in a significant reduction in neuronal injury. 263 
Pharmacologic Effect of Corticosteroids
Hypercorticism and Adrenal Suppression
Cushing syndrome is a characteristic pattern of obesity associated with hypertension that results from abnormally high blood levels of cortisol produced by the adrenal cortex. Exogenous administration of glucocorticoids can result in an identical clinical pattern and is frequently called ''cushingoid'' syndrome. The active corticosteroid in MPA and other depot steroid preparations is slowly released over a period of days to weeks. Common mineralocorticoid effects such as fluid retention and weight gain, as well as increased blood pressure and congestive heart failure, have been reported after ESI. Cushingoid adverse effects beginning several weeks after ESI have also been reported.
264Y266
These can include facial swelling, buffalo hump, skin bruising, and scaly skin lesions.
Jacobs et al 267 documented marked suppression of plasma cortisol levels in 12 patients who each received a single epidural injection of 80 mg MPA. Plasma cortisol and adrenocorticotropic hormone (ACTH) levels were significantly depressed at 1, 7, 14, and 21 days after treatment. The ability of exogenous ACTH to increase plasma cortisol levels was also reduced over a 3-week period. Kay et al 268 sought to determine the adrenal response to a series of 3 weekly epidural injections of 80 mg triamcinolone diacetate and to ascertain whether the preinjection administration of midazolam had any effect. Suppression of serum cortisol and ACTH began within 45 minutes of the initial injection and remained low for 7 days after each of the first 2 injections. At 34 days after the last injection, ACTH and cortisol levels were suppressed only in the group that received midazolam before the procedures.
Another symptom of hypercorticism is steroid-induced myopathy, which is characterized by progressive proximal muscle weakness, increased serum creatinine kinase levels, and a myopathic electromyography and muscle biopsy specimen. This has been reported following a single epidural dose of triamcinolone. 269 All patients who have been taking steroids for long periods develop reversible myofiber atrophy, which should be distinguished from true steroid myopathy.
Because severe cases of Cushing syndrome and adrenal suppression have been described after a single, relatively small steroid dose, it is unlikely that this complication can be avoided in susceptible patients. The most prudent guiding principle is to use repeated steroid injections only in those who experience significant benefit and to space the injections at long-enough intervals to allow complete recovery of adrenal function. Patients undergoing surgery within a few weeks of receiving deposteroids should be evaluated for adrenal suppression or should receive stress steroid coverage during the perioperative period.
Altered Glucose Tolerance
Glucocorticoid administration reduces the hypoglycemic effect of insulin and interferes with blood glucose control in diabetic patients. 270 Following injection of depo-steroids, diabetic patients generally experience significant increases in blood glucose levels and insulin requirements for 1 to 2 days after injection. A study of 30 diabetic patients demonstrated significant changes in blood glucose levels that normalized within 2 days after ESI. 271 The mean blood glucose level before ESI was 160, which increased to 286 immediately after injection. There was no correlation between glucose control (Hb A1c levels before injection) and response. Long-term indices of disease were followed in 9 diabetic patients after a single ESI of 80 mg depo-MPA and were determined to have no effect on glycemic control. 272 Patients with diabetes receiving ESI should be counseled that blood glucose may increase after intervention, but that the effects should dissipate within 2 days. Glucose levels in diabetic patients should be monitored closely during the first 2 days following any type of steroid injection. Patients need to be informed that adjustment of their insulin dose may be required. Patients with brittle diabetes should consult their internist or endocrinologist before initiating steroid treatment.
DURAL PUNCTURE
Accidental dural puncture during attempted epidural injection is associated with a headache incidence of greater than 50%. 273 The headache incidence among patients undergoing attempted ESI appears to be much lower, perhaps due to the older patient population, the smaller-gauge needles used, and/or the widespread use of fluoroscopic guidance. In a large retrospective analysis that included 284 IL epidural injections, only 1 postdural puncture headache was reported, for an overall incidence of 0.004%. 91 Introduction of air into the subdural or subarachnoid space during attempted epidural needle placement can produce pneumocephalus and an immediate headache that can last up to several days. Although the most common cause of pneumocephalus following ESI is accidental dural puncture resulting in the introduction of air during the loss-of-resistance technique, 274 ,275 a pneumocephalus headache has been reported after a cervical ESI performed using the hanging-drop technique. 276 In light of the fact that cervical epidural pressures are nearly always positive in the prone position, this is more likely to occur during a cervical ESI performed in the sitting position, in which pressures tend to be negative. 277 There is evidence that the use of a smaller-gauge needle increases the chances of incorrect needle placement, 278 but unlike for epidural anesthesia, the effect of using smaller epidural needles for ESI on the incidence of postdural puncture headache is unknown. Conservative management of postdural puncture headache includes bed rest, hydration, caffeine, and mild analgesics. 279 Following known dural puncture, an epidural blood patch can quickly and effectively reduce or eliminate the ensuing spinal headache.
BLEEDING COMPLICATIONS
Intraspinal bleeding is a potentially devastating complication that can result in paraplegia or quadriplegia. Back pain and headache may be the presenting complaints. Both epidural 280 and subdural 281 hematomas have been reported following ESIs in patients without coagulopathy or concurrent use of anticoagulants. Benzon et al 282 reported a case of quadriplegia following a cervical ESI in a patient who had been taking clopidogrel and diclofenac. Following surgical decompression, the patient regained upper-extremity function, but his lower extremities remained paralyzed. The earlier Closed Claims Study cites 2 cases of spinal cord injury resulting from epidural hematomas following ESI, 231 with both patients having been receiving anticoagulants. In the subsequent Closed Claims analysis of cervical procedures, Rathmell et al 253 reported 3 cases of epidural hematoma (5% of cervical claims), one of which occurred a month after the procedure and was felt to be unrelated; the use of anticoagulants or coagulopathy was not reported. The most important risk factor for bleeding is coagulopathyVeither primary or pharmacological. Anticoagulants and antiplatelet drugs such as clopidogrel are contraindications to epidural injections of any sort. On the other hand, NSAIDs, including aspirin, do not appear to appreciably increase the risk of epidural bleeding. Horlocker et al 283 reported no major hemorrhagic complications among 1035 patients, one-third of whom had been taking NSAIDs (134 on aspirin, 249 on other NSAIDs, and 34 on multiple drugs) who underwent 1214 ESIs. The only published reports of epidural hematomas resulting in neurologic complications have occurred following cervical injections. Given the rarity of this complication, no conclusions regarding relative risk of cervical versus lumbar epidural injections can be drawn. The discontinuation of medications in patients receiving antithrombotic or thrombolytic therapies before ESI is not devoid of risks and should be handled in the same fashion recommended for other regional anesthetics. 284 In an online survey conducted in 325 respondents (of 2300 surveyed) who perform interventional pain management procedures, nearly 3 times as many thromboembolic complications (n = 162) were reported as were serious bleeding complications (n = 55). 285 Among the thromboembolic events, 153 occurred following discontinuation of anticoagulation therapy, whereas 9 transpired despite antiplatelet therapy being continued. For the bleeding complications, 29 occurred after warfarin or antiplatelet therapy was discontinued, with 26 occurring in the context of continued anticoagulation treatment. These findings suggest that the decision to discontinue anticoagulation therapy for neuraxial injections must be made after careful consideration of the risks and benefits, in consultation with a specialist. Because of its location at the distal end of the spinal column, its shallow depth (which enables compression), and the fact that it can easily be accessed with a small gauge needle, the caudal approach might be considered when an ESI is strongly indicated and the risk of discontinuing warfarin or antiplatelet therapy is high.
INFECTIOUS COMPLICATIONS
Infectious complications following epidural or intra-articular injections are rare. Epidural abscess is a condition that can occur spontaneously, in the absence of injection or instrumentation of the spinal canal. Tang et al 286 reviewed 46 cases of spontaneous epidural abscess and found that 46% occurred in diabetic patients. Common presenting symptoms included paralysis (80%), localized spinal pain (89%), radicular pain (57%), and chills and fever (67%). The erythrocyte sedimentation rate was always elevated, and Staphylococcus aureus was the organism isolated in about half the cases. Hooten et al 287 recently performed a literature review examining the cases of epidural abscess following ESI. They found 14 cases, 2 of which also presented with meningitis. A synopsis of the patient characteristics and outcomes for those cases as well as another case 288 not included in that review is shown in Table 7 .
Infection was listed in the original Closed Claims Study 231 as a cause for litigation in 24 cases involving ESI. There were 12 cases of meningitis, 3 cases of osteomyelitis, and 7 reports of epidural abscess; 2 cases involved multiple infection sites. Among the 7 cases of epidural abscess, 6 required surgical decompression, and 1 resulted in permanent lower-extremity motor dysfunction. In 1 claim, there were both meningitis and epidural abscess and, in another, a combination of meningitis, abscess, and osteomyelitis. A single case of bacterial diskitis was reported following caudal ESI. 289 This occurred following injection of 120 mg triamcinolone in a 73-year-old woman with mild diabetes mellitus. One month after injection, she returned with increased back pain. Magnetic resonance imaging revealed L4-5 diskitis and adjacent osteomyelitis. Biopsy culture grew Pseudomonas aeruginosa. She was successfully treated with intravenous ciprofloxacin and gentamicin. In the Closed Claims analysis of cervical procedures, infection or abscess was reported in 3 cases (5% of procedures). 253 Until the recent outbreak associated with contaminated steroids in the United States, fungal infection following ESI was considered to be an extremely rare complication. A case of ''torula meningitis'' was reported by Shealy 290 more than 40 years ago following an intrathecal injection of MPA. No details of the case, such as the time course after injection or the outcome, were presented. Another case involved the formation of an Aspergillus abscess in the spinal canal 6 weeks following the last of 3 ESIs performed in a healthy 31-year-old woman. 291 An outbreak of fungal infections of the central nervous system occurred in the United States in late 2012 among patients who received ESI with preservative-free MPA prepared by a single compounding pharmacy. The median age of the 66 case patients was 69 years (range, 23Y91 years), with the median time from the last epidural injection to the development of symptoms being 18 days (range, 0Y56 days). The presenting symptoms included meningitis alone (73%), cauda equina syndrome or focal infection (15%), and posterior circulation stroke, with or without meningitis (12%). At the time of admission, signs and symptoms were headache (in 73% of patients), new-onset or worsening back pain (in 50%), neurologic symptoms such as vertigo (in 48%), nausea (in 39%), and stiff neck (in 29%). A total of 21 patients had laboratory confirmation of Exserohilum rostratum infection, with 1 person developing an Aspergillus fumigatus infection. The risk of infection increased with exposure to a single lot of the compounded drug, older vials, higher administered doses, multiple procedures, female sex, age older than 60 years, and using an IL approach to epidural entry, which is associated with a higher risk of dural puncture. As of late December 2012, more than 650 cases of fungal infection and 39 deaths have been reported. 229, 292 Rapid recognition of illness and prompt initiation of therapy are the cornerstones of management for infectious complications. Practitioners involved in the care of these patients were utilizing a compounding pharmacy that fell outside the direct regulatory oversight of the US Food and Drug Administration. This compounding pharmacy was preparing large batches of single-use, preservative-free vials of a depot formulation of MPA and marketing and distributing them widely across the United States. Numerous reasons appear to have led practitioners to purchase from a compounding pharmacy rather than a pharmaceutical company, including fears of potential patient harm and litigation surrounding use of preservative containing solutions, better availability, and lower costs. The long-term implications of this outbreak are still emerging.
Meticulous sterile technique with attention to skin preparation should prevent the large majority of infectious complications. Steroid injections should be avoided if there is any active infection. The incidence of infection following ESI is too low to justify routine prophylactic antibiotic use, and there are no data to support the benefit of prophylaxis in immunocompromised patients. Routine preprocedure antibiotic administration can lead to the development of resistant strains of pathogens. There is now increasingly widespread antibiotic resistance among strains of S. aureus, and patients coming for elective procedures are often carriers of resistant organisms. 293 Most cases of epidural abscess require surgical drainage. Surgical decompression is urgently indicated if there is any neurologic compromise. While waiting for cultures, treatment with antibiotics that cover S. aureus and Staphylococcus epidermidis is appropriate, as these are the most commonly isolated organisms. 294 
OTHER ADVERSE EFFECTS AND COMPLICATIONS
A decrease in bone marrow density in postmenopausal women was reported in a retrospective study performed in patients who had received a cumulative ESI dose of greater than 120 mg methylprednisolone compared with a control group treated with NSAIDs and muscle relaxants. 295 In a follow-up study by the same group performed in 352 postmenopausal who had been treated with ESI, the authors found no association between the incidence of pathological fractures and either the number or total dose of glucocorticoids. 296 Vasovagal reactions, with resultant bradycardia, hypotension, nausea, and/or altered consciousness, are fairly common among patients undergoing interventional procedures. The incidence of vasovagal reactions during ESIs was shown to be significantly higher for patients undergoing cervical epidural injections (8%) than for those undergoing lumbar epidurals (1%). 297 In a recent retrospective study conducted by McGrath et al, 91 the most common complications associated with ESI were increased pain (1.1%), pain at injection site (0.33%), and persistent numbness (0.14%).
Complications were less common with TF injections (2.1%) than during IL injections (6.0%).
In summary, serious complications from injection of corticosteroid suspensions into the epidural space are uncommon, but complications can be devastating. Patients should be instructed to promptly report neurologic changes, new or increasing pain, headache, and fever. A system of night and weekend coverage should be available, and patients should know how to contact the on-call physician. There is a real possibility that if the patient later develops arachnoiditis as a result of ongoing disease or surgery, it may be attributed to the injection. At this time, there is no evidence that epidural injection of steroids, without dural puncture, will produce either aseptic meningitis or arachnoiditis.
SUMMARY
In summary, ESIs appear to provide some pain relief and functional improvement in well-selected candidates for at least 6 weeks. The evidence for more prolonged benefit or for a surgerysparing effect is conflicting. Transforaminal ESIs are more effective than other routes of administration, and depo-steroids appear to provide longer pain relief than nondepot formulations. However, the risks associated with the TF administration of depo-steroids in the upper lumbar, thoracic, and cervical regions preclude their use as a first-line treatment. Higher volumes may be associated with better outcomes, and there is some evidence that the epidural injection of nonsteroid solutions may also have analgesic effects. Although comparative-effectiveness studies are lacking, consensus guidelines recommend that the number of ESI be tailored based on individual response, rather than performed as a fixed series. We are of the firm belief that ESIs should continue to be part of a multimodal treatment strategy, but that they be used in a manner based on empirical evidence, rather than done as a rote treatment in any patient with spine pain. 
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